Wipro helped a top pharma company develop a non-invasive solution to ensure best health outcome for renal transplant patients

Client Background

The client is a Big Pharma headquartered in New York City. It manufactures prescription drugs in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Industry Landscape

Amid the revenue pressures triggered by patent cliff and the imperatives of outcome-based healthcare, Life Sciences organizations are recognizing the increased role of patients in disease management. Thus, they need innovative models to engage their target actors - Patients and Physicians.

Opportunity

Our client launched a speciality nephrology drug used as immunosuppressant post renal transplants, the first such drug to be approved in more than a decade. Despite a limited market, the drug was expected to be highly profitable and increase our client’s market share significantly. The client wanted to ensure that the drug delivers the expected health outcome and repeat Rx (prescription) and patient satisfaction.

Solution

Wipro was tasked with creating a solution to ensure expected health outcome of the nephrology drug while helping with repeat Rx and patient satisfaction.

We conducted requirement gathering sessions with: 

• The medical team - to understand details of drug usage and pathology for vitals analysis.
• The brand team - to understand the imperatives of brand experience.
• The compliance team - to understand regulatory mandates such as patient data privacy, drug administration safety

We conducted requirement gathering sessions with:

• The medical team - to understand details of drug usage and pathology for vitals analysis
• The brand team - to understand the imperatives of brand experience
• The compliance team - to understand regulatory mandates such as patient data privacy, drug administration safety, etc.

We developed a platform-independent mobile app, which, according to the Medical Devices Directive, in its own right qualifies as a Class I medical device owing to its use and for its safety and efficacy.

The app facilitates physicians with:

•  Analysis of vital parameters post transplant to ensure the patient’s body is accepting the new organ, by successfully converting a medical algorithm to software for the first time
  
•  Keeping a check on cardio vascular risks through a CV Risk Calculator
•  Accurate calculation of the dosage to be administered, based on the patient’s vitals and history through a dosage calculator
•  Getting a one-touch access to all clinical, medical and safety information pertaining to the drug, its constitution and instructions on reconstitution, dilution, administration, storage, etc

Wipro created a security feature so that only registered physicians could use the app. A process was designed to validate credentials with the master ANA DB server. We also created web services so that the app could connect to the server through cloud.

The integration was unique with the mobile app on cloud and in-house server behind the firewall.

Our in-house regulatory consultant ensured the app had robust human error correction mechanism through in-person sessions with the User Acceptance Testing (UAT) HCP group.

Business Impact

• Increased revenue by 30% due to increased Rx for a 2.5 million patient base
• Assured health outcome increasing acceptance of transplanted organ
  • Enhanced drug efficacy through timely and accurate administration
  • Reduced risk of adverse events post transplant like fatal infections, toxicity, cardio vascular complications and malignancy
  • Fast response to allergic reaction to drug through real-time condition update

 Improved drug adherence

• Engagement of Key Opinion Leaders Physicians by empowering them with one touch mobile access to drug literature and prescription modification based on vitals analysis and feedback on drug efficacy and adverse events.
• The robust integration of the mobile app on cloud with in-house server for authentication and authorization of registered HCPs ensured liability reduction for our client
• Uniform brand experience and increased brand recall through app GUI